Perioperative chemotherapy for upper tract urothelial cancer

[1]  S. Shariat,et al.  Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. , 2012, Urologic oncology.

[2]  V. Margulis,et al.  Upper tract urothelial carcinoma: impact of time to surgery. , 2012, Urologic oncology.

[3]  W. Roberts,et al.  Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. , 2012, Journal of endourology.

[4]  K. Bensalah,et al.  The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. , 2012, European urology.

[5]  M. Dimopoulos,et al.  Outcomes after adjuvant chemotherapy in the treatment of high‐risk urothelial carcinoma of the upper urinary tract (UUT‐UC) , 2011, Cancer.

[6]  T. O'brien,et al.  Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). , 2011, European urology.

[7]  C. Kwak,et al.  Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. , 2011, Urologic oncology.

[8]  C. Dinney,et al.  Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. , 2011, Urology.

[9]  S. Ito,et al.  Single-center outcome of laparoscopic unilateral adrenalectomy for patients with primary aldosteronism: lateralizing disease using results of adrenal venous sampling. , 2011, Urology.

[10]  J. Raman,et al.  The role of lymphadenectomy for upper tract urothelial carcinoma , 2011, Nature Reviews Urology.

[11]  M. Jinzaki,et al.  Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. , 2011, The Journal of urology.

[12]  O. Cussenot,et al.  Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. , 2011, Urologic oncology.

[13]  Y. Lotan,et al.  Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? , 2011, Urologic oncology.

[14]  Zhongfa Zhang,et al.  Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder , 2010, BMC Medical Genomics.

[15]  S. Shariat,et al.  Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. , 2010, The Journal of urology.

[16]  J. Coleman,et al.  Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? , 2010, European urology.

[17]  M. Stifelman,et al.  Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. , 2010, European urology.

[18]  Y. Lotan,et al.  Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. , 2010, The Journal of urology.

[19]  R. Millikan,et al.  Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma , 2010, Cancer.

[20]  N. Miyanaga,et al.  Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up study , 2010, International journal of urology : official journal of the Japanese Urological Association.

[21]  Y. Lotan,et al.  Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. , 2010, The Journal of urology.

[22]  B. Lane,et al.  Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy , 2010, Cancer.

[23]  S. Shariat,et al.  Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. , 2010, European urology.

[24]  K. Bensalah,et al.  Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. , 2010, European urology.

[25]  K. Bensalah,et al.  Advanced patient age is associated with inferior cancer‐specific survival after radical nephroureterectomy , 2009, BJU international.

[26]  N. Cho,et al.  Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. , 2009, Urology.

[27]  F. Montorsi,et al.  Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. , 2009, European journal of cancer.

[28]  K. Bensalah,et al.  Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. , 2009, Urology.

[29]  P. Tamboli,et al.  Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. , 2009, Archives of pathology & laboratory medicine.

[30]  K. Bensalah,et al.  Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. , 2009, The Journal of urology.

[31]  M. Gallucci,et al.  Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. , 2009, European urology.

[32]  K. Bensalah,et al.  The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? , 2009, European urology.

[33]  K. Bensalah,et al.  Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. , 2009, European urology.

[34]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[35]  K. Bensalah,et al.  Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. , 2009, The Journal of urology.

[36]  V. Margulis,et al.  Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Bensalah,et al.  TUMOR NECROSIS IS AN INDICATOR OF AGGRESSIVE BIOLOGY IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT , 2009 .

[38]  M. Gallucci,et al.  Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma , 2009, BJU international.

[39]  P. Carroll,et al.  The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. , 2009, European urology.

[40]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[41]  K. Bensalah,et al.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi‐institutional analysis of 1363 patients , 2009, BJU international.

[42]  K. Bensalah,et al.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Y. Sugimura,et al.  Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma , 2008, International journal of urology : official journal of the Japanese Urological Association.

[44]  O. Cussenot,et al.  Molecular and histological markers in urothelial carcinomas of the upper urinary tract , 2008, BJU international.

[45]  P. Alken,et al.  Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. , 2008, Urology.

[46]  R. Millikan,et al.  A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): Final results from the M.D. Anderson Cancer Center , 2008 .

[47]  O. Gofrit,et al.  Vesical vs. extra-vesical patterns of recurrence after the treatment of urothelial upper tract tumors. , 2008, Urologic oncology.

[48]  J. Oxley,et al.  Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. , 2008, Journal of endourology.

[49]  H. Miyake,et al.  Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. , 2008, Urology.

[50]  N. Cho,et al.  Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. , 2007, Urology.

[51]  H. Grossman,et al.  Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. , 2007, Urology.

[52]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[53]  M. Stöckle,et al.  Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. , 2007, European urology.

[54]  F. Hamdy,et al.  Behavior of urothelial carcinoma with respect to anatomical location. , 2007, The Journal of urology.

[55]  Badrinath R Konety,et al.  Bladder and upper tract urothelial cancer. , 2007, The Journal of urology.

[56]  P. Rehak,et al.  404: Bladder Tumor Development after Urothelial Carcinoma of the Upper Urinary Tract is Related to Primary Tumor Location , 2007 .

[57]  K. Mita,et al.  Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. , 2007, Japanese journal of clinical oncology.

[58]  C. Wood,et al.  Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? , 2006, BJU international.

[59]  P. Rehak,et al.  Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location , 2006, BJU international.

[60]  P. Rehak,et al.  Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. , 2006, The Journal of urology.

[61]  S. Suster,et al.  Micropapillary Urothelial Carcinoma of the Upper Urinary Tract , 2006 .

[62]  C. Kwak,et al.  Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. , 2006, Urology.

[63]  S. Suster,et al.  Micropapillary urothelial carcinoma of the upper urinary tract: Clinicopathologic study of five cases. , 2006, American journal of clinical pathology.

[64]  I. H. Chang,et al.  Adjuvant Chemotherapy in the Management of pT3N0M0 Transitional Cell Carcinoma of the Upper Urinary Tract , 2006, Urologia Internationalis.

[65]  F. Hamdy,et al.  Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. , 2006, The Journal of urology.

[66]  Y. Lotan,et al.  Cancer specific outcomes in patients with pT0 disease following radical cystectomy. , 2006, The Journal of urology.

[67]  S. Johansson,et al.  Micropapillary carcinoma of the renal pelvis and ureter. , 2006, The Journal of urology.

[68]  T. Tzai,et al.  Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. , 2005, Urology.

[69]  S. Boorjian,et al.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology , 2005, BJU international.

[70]  F. Marshall.  Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. , 2005, Journal of Urology.

[71]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[72]  J. Rassweiler,et al.  Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? , 2004, European urology.

[73]  A. Zietman,et al.  Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. , 2004, The Journal of urology.

[74]  W. Oh,et al.  A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. , 2004, Urologic oncology.

[75]  M. Dimopoulos,et al.  Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Manola,et al.  Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium , 2004, Cancer.

[77]  M. Dimopoulos,et al.  Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[79]  E. Tuzel,et al.  Transitional cell carcinoma of the ureter and renal pelvis. , 2003, Critical reviews in oncology/hematology.

[80]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[81]  D. Neal,et al.  Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. , 2003, Urology.

[82]  M. Droller.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. , 2002, The Journal of urology.

[83]  J. Cheville,et al.  Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.

[84]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  L. Ellison,et al.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. , 2000, The Journal of urology.

[86]  S. Mcneill,et al.  The long‐term outcome after laparoscopic nephroureterectomy: a comparison with open nephroureterectomy , 2000, BJU international.

[87]  N. Masumori,et al.  Risk factors for the development of bladder cancer after upper tract urothelial cancer. , 2000, Urology.

[88]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[89]  M. Droller.  Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial , 1999, The Lancet.

[90]  T. Carmody,et al.  Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. , 1998, Urology.

[91]  C. Roehrborn,et al.  Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. , 1998, The Journal of urology.

[92]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[93]  D. Bagley,et al.  Upper-tract transitional cell carcinoma. , 1997, Urology.

[94]  M. Bibbo,et al.  Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. , 1997, The Journal of urology.

[95]  M. Blute,et al.  Platinum-Chemotherapy for Advanced Transitional Cell Carcinoma of the Upper Urinary Tract , 1996 .

[96]  C. Dinney,et al.  Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. , 1996, Urology.

[97]  S. Mondillo,et al.  Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.

[98]  H. Zincke,et al.  Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. , 1996, Mayo Clinic proceedings.

[99]  S. Smalley,et al.  Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. , 1995, Urology.

[100]  H. Shiina,et al.  Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. , 1995, Urologia internationalis.

[101]  J. Rassweiler.  [Neoadjuvant chemotherapy of invasive bladder cancer]. , 1994, Der Urologe. Ausg. A.

[102]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  S. Smalley,et al.  Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. , 1992, International journal of radiation oncology, biology, physics.

[104]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[105]  O. Dalesio,et al.  Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response. , 1989, Progress in clinical and biological research.

[106]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.